nach oben

Supportive Care in Cancer

Erschienen in:

01.02.2012 | Original Article

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study

verfasst von: Laura Amodeo, Lorys Castelli, Paolo Leombruni, Daniela Cipriani, Alessia Biancofiore, Riccardo Torta

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study aimed to compare the tolerability and efficacy of two different titrations of paroxetine (slow and standard) in a population of cancer patients with depression.

Methods

This randomized open trial included 30 cancer patients with depression (major depressive disorder, dysthymic disorder, or adjustment disorder with depressed mood) and aimed to compare the safety of slow up-titration (arm A) versus standard up-titration (arm B) of paroxetine chlorhydrate. In both arms, the maximum final dose was 20 mg/day. Patients were evaluated at baseline and after 2, 4, and 8 weeks with rating scales for depression and anxiety (MADRS, HADS, HAM-A, CGI), quality of life (EORTC-QLQ-30), and side effects (DOTES, SIDE).

Results

Thirty consecutive cancer patients (F = 21; M = 9) meeting DSM-IV TR criteria for mood disorders (MD) were enrolled in the study and randomly assigned to slow or standard paroxetine titration. Both treatment groups showed a significant mood improvement (change in MADRS total score) from baseline to end point (arm A—F(2,18) = 33.68 p < 0.001; arm B—F(2,12) = 6.97 p < 0.005). A significantly higher rate of patients in arm A compared with arm B showed no side effects after 2 weeks (40% vs. 6.7%, respectively). A multinomial logistic regression confirmed such differences between arms (chi square = 20.89 p = 0.004). The self-evaluating scale (SIDE) confirmed this difference: 60% of subjects in arm B perceived side effects compared to only 11.1% of patients in arm A.

Conclusions

The results of this study suggest that slow paroxetine up-titration is better tolerated and at least as effective as the standard paroxetine up-titration in cancer patients with depression.

Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54(3):269–282PubMedCrossRef

Hamer M, Chida Y, Molloy GJ (2009) Psychological distress and cancer mortality. J Psychosom Res 66(3):255–258, Epub 2009 Jan 16PubMedCrossRef

Smith E, Gomm S, Dickens C (2003) Assessing the independent contribution to quality of life from anxiety and depression in patients with advanced cancer. Palliat Med 17(6):509–513PubMedCrossRef

Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004(32):57–71CrossRef

Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr (32):32–39

Angelino AF, Treisman GJ (2001) Major depression and demoralization in cancer patients: diagnostic and treatment considerations. Support Care Cancer 9(5):344–349PubMedCrossRef

Rodin G, Lloyd N, Katz M, Green E, Mackay JA, Wong RK (2007) The treatment of depression in cancer patients: a systematic review. Support Care Cancer 15(2):123–136, Epub 2006 Oct 21PubMedCrossRef

Strong V, Waters R, Hibberd C, Murray G, Wall L, Walker J, McHugh G, Walker A, Sharpe M (2008) Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet 372(9632):40–48PubMedCrossRef

Torta R, Siri I, Caldera P (2008) Sertraline effectiveness and safety in depressed oncological patients. Support Care Cancer 16(1):83–91, Epub 2007 Sep 14PubMedCrossRef

10.

Rodin G (2008) Treatment of depression in patients with cancer. Lancet 372(9632):8–10PubMedCrossRef

11.

Bull SA, Hu XH, Hunkeler EM et al (2002) Discontinuation of use and switching of antidepressants: influence of patient–physician communication. JAMA 288:1403–1409PubMedCrossRef

12.

Beasley CM Jr, Koke SC, Nilsson ME, Gonzales JS (2000) Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 22:1319–1330PubMedCrossRef

13.

Kobak KA, Taylor L, Katzelnick DJ et al (2002) Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry 63:727–732PubMedCrossRef

14.

Masand PS (2003) Tolerability and adherence issues in antidepressant therapy. Clin Ther 25(8):2289–2304PubMedCrossRef

15.

Young AS, Klap R, Sherbourne CD, Wells KB (2001) The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 58:55–61PubMedCrossRef

16.

Rosholm JU, Andersen M, Gram LF (2001) Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 56:923–929PubMedCrossRef

17.

Onishi H, Yamamoto W, Wada M, Nishida T et al (2007) Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature. Palliat Support Care 5(4):411–414PubMedCrossRef

18.

Sinclair LI, Christmas DM, Hood SD, Potokar JP et al (2009) Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 194(6):483–490PubMedCrossRef

19.

Barbui C, Hotopf M, Freemantle N, Boynton J et al (2007) WITHDRAWN: treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs). Cochrane Database Syst Rev 18(3):CD002791

20.

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, fourth edition, text revision. American Psychiatric Association, WashingtonCrossRef

21.

Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389PubMedCrossRef

22.

Guy W. (1976) DOTES: dosage record and treatment emergent symptom scale. In: Rockville GW (ed) ECDEU assessment manual for psychopharmacology, rev. ed. National Institute of Mental Health Rockville, MD, USA.

23.

Conti L. Gli effetti indesiderati dei trattamenti psicofarmacologici. (2000) In Conti L. "Repertorio delle scale di valutazione in psichiatria". S.E.E. (ed) Firenze, Italy. p. 1533–1544

24.

Musselman DL, Lawson DH, Gumnick JF, Manatunga AK et al (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961–966PubMedCrossRef

25.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef

26.

Kearns NP, Cruickshank CA, McGuigan KJ, Riley SA, Shaw SP, Snaith RP (1982) A comparison of depression rating scales. Br J Psychiatry 141:45–49PubMedCrossRef

27.

Zimmerman M, Posternak MA, Chelminski I (2004) Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 19(4):215–220PubMedCrossRef

28.

Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G (1999) Detecting psychological distress in cancer patients: validity of the Italian version of the hospital anxiety and depression scale. Support Care Cancer 7(3):121–127PubMedCrossRef

29.

Zimmerman M, Posternak MA, Chelminski I (2004) Derivation of a definition of remission on the Montgomery–Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 38(6):577–582PubMedCrossRef

30.

Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedCrossRef

31.

Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M (2010) Antidepressants for depression in physically ill people. Cochrane Database Syst Rev (3):CD007503. doi:10.1002/14651858.CD007503.pub2

32.

Williams S, Dale J (2006) The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 94:372–390PubMedCrossRef

33.

Fisch MJ, Loehrer PJ, Kristeller J, Passik S et al (2003) Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier oncology group. J Clin Oncol 21:1937–1943PubMedCrossRef

34.

Morrow GR, Hickok JT, Roscoe JA, Raubertas RF et al (2003) Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 21:4635–4641PubMedCrossRef

35.

Roscoe JA, Morrow GR, Hickok JT, Mustian KM et al (2005) Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89:243–249PubMedCrossRef

36.

Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M et al (1996) The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94:205–210PubMedCrossRef

37.

Van Heeringen K, Zivkov M (1996) Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 169:440–443PubMedCrossRef

38.

Pezzella G, Moslinger-Gehmayr R, Contu A (2001) Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70(1):1–10PubMedCrossRef

39.

Weitzner MA, Moncello J, Jacobsen PB, Minton SJ (2002) A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. Pain Symptom Manage 23(4):337–345CrossRef

40.

Chi-Un P, Kim Y-J, Won W-Y, Kim H-J et al (2004) Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Hum Psychopharmacol Clin Exp 19-1:25–29

41.

Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker T (1992) The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 33:521–523PubMed

42.

Kaye CM, Haddock RE, Langley PF et al (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 80(350):60–75CrossRef

43.

Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa Kl (2002) Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 62:655–703PubMedCrossRef

44.

Musselman DL, Somerset WI, Guo Y, Manatunga AK et al (2006) A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 67(2):288–296PubMedCrossRef

Titel: Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study
verfasst von: Laura Amodeo
Lorys Castelli
Paolo Leombruni
Daniela Cipriani
Alessia Biancofiore
Riccardo Torta
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 2/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1118-8

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study